Pemazyre (pemigatinib) — CareFirst (Caremark)

Initial criteria

• Diagnosis of myeloid/lymphoid neoplasm with FGFR1 rearrangement

Reauthorization criteria

• No evidence of unacceptable toxicity or disease progression while on current regimen

Approval duration

12 months